SPARCL1 and colorectal carcinoma: Naschberger and colleagues, analyzing the transcriptome of tumor-associated EC, demonstrated that SPARCL1 expression is progressively lost in EC derived from CRC tumors, characterized by worse clinical prognosis [147].